Oculus, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$1.9Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
138clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Pentacam $191K associated (2023-2025)
- Ctr/Jenvis $124K associated (2023-2025)
- Keratograph $101K associated (2023-2025)
- Ipl/Darwin $60K associated (2023-2025)
- Keratograph 5m $53K associated (2023-2025)
- Myopia Master $52K associated (2023-2025)
- Na $38K associated (2023-2025)
- Ipl Program $24K associated (2023-2025)
- Pentacam Axl Wave $15K associated (2023-2025)
- Luvo Ipl $8,483 associated (2023-2025)
- Pentacam Oct $6,000 associated (2023-2025)
- Pentacam/Myopia Master/Pentacam Axl Wave $2,500 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Crystal Brimer | Wilmington, NC | Optometrist | $611,601.33 |
| Jack Holladay | Bellaire, TX | $240,000.00 | |
| Steven Eiden | Deerfield, IL | Optometrist | $182,200.00 |
| Marguerite Mcdonald | Oceanside, NY | Ophthalmology | $120,667.31 |
| Arun Gulani | Jacksonville, FL | $115,995.00 | |
| Paul Karpecki | Lexington, KY | Optometrist | $110,000.00 |
| Rolando Toyos | Memphis, TN | Ophthalmology | $97,130.00 |
| Thomas Weshefsky | Myrtle Beach, SC | Optometrist | $73,892.15 |
| Kevin Chan | Tysons Corner, VA | Pediatrics (Optometrist) | $58,238.78 |
| Michael Belin | Slingerlands, NY | Ophthalmology | $55,341.24 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.